Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the european prospective investigation into cancer and nutrition (EPIC)

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 1, 2011, Pages 208-214

  Franceschi, Silvia ^a   Lise, Mauro ^b   Trepo, Christian ^c   Berthillon, Pascale ^c   Chuang, Shu Chun ^d   Nieters, Alexandra ^e   Travis, Ruth C ^f   Vermeulen, Roel ^g   Overvad, Kim ^h   Tjønneland, Anne ⁱ   Olsen, Anja ⁱ   Bergmann, Manuela M ^j   Boeing, Heiner ^j   Kaaks, Rudolf ^k   Becker, Nikolaus ^k   Trichopoulou, Antonia ^l,m   Lagiou, Pagona ^l   Bamia, Christina ^l   Palli, Domenico ⁿ   Sieri, Sabina ^o   Panico, Salvatore ^p   Tumino, Rosario ^q   Sacerdote, Carlotta ^r   Bueno De Mesquita, Bas ^g,s   Peeters, Petra H M ^d,g   Rodríguez, Laudina ^t   Barroso, Leila Luján ^u   Dorronsoro, Miren ^v,w   Sánchez, María José ^w,x   Navarro, Carmen ^w,y   Barricarte, Aurelio ^w,z   Regnér, Sara ^aa   Borgquist, Signe ^aa   Melin, Beatrice ^ab   Hallmans, Göran ^ac   Khaw, Kay Tee ^ad   Wareham, Nick ^ae   Rinaldi, Sabina ^a   Hainaut, Pierre ^a   Riboli, Elio ^d   Vineis, Paolo ^d   more..

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c INSERM   (France)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h AARHUS UNIVERSITY   (Denmark)

ⁱ INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^j GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^k GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^l UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^m HELLENIC HEALTH FOUNDATION   (Greece)

ⁿ CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^o NATIONAL CANCER INSTITUTE   (Italy)

^p UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^q District 1 Hospital   (Italy)

^r CPO Piemonte   (Italy)

^s NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^t Health and Health Care Services Council   (Spain)

^u CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^v Basque Government   (Spain)

^w CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^x ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^y Regional Health Authority   (Spain)

^z INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^aa LUND UNIVERSITY HOSPITAL   (Sweden)

^ab UMEÅ UNIVERSITY   (Sweden)

^ac UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^ad UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^ae INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HODGKIN DISEASE; HUMAN; LYMPHOID TISSUE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RISK;

CASE-CONTROL STUDIES; EUROPE; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 78651457456     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0889     Document Type: Article

References (40)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46:765-81.
2. Jaffe ES, Harris NL, Stein H, Vardiman J. World Health Organisation Classification of Tumours: Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
3. Bosetti C, Levi F, Ferlay J, Lucchini F, Negri E, La Vecchia C. Incidence and mortality from non-Hodgkin lymphoma in Europe: the end of an epidemic? Int J Cancer 2008;123:1917-23.
4. Hirabayashi Y, Katanoda K. Comparison of time trends in multiple myeloma incidence (1973-1997) in East Asia, Europe and United States, from Cancer Incidence in Five Continents, Vols IV-VIII. Jpn J Clin Oncol 2008;38:720-1.
5. Adamson P, Bray F, Costantini AS, Tao MH, Weiderpass E, Roman E. Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe. Eur J Cancer 2007;43:391-401.
6. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-76.
7. Pagano JS. Viruses and lymphomas. N Engl J Med 2002;347: 78-9.
8. Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S. B-cell non- Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 2004;111:1-8.
9. Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006;15:2078-85.
10. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non- Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008;6:451-8.
11. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens- part B: biological agents. Lancet Oncol 2009;10:321-2.
12. Nath A, Agarwal R, Malhotra P, Varma S. Prevalence of hepatitis B virus infection in non-Hodgkin's lymphoma: a systematic review and meta-analysis. Intern Med J 2010;40:633-41.
13. Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 2010;11:827-34.
14. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
15. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001;8:87-95.
16. Chevaliez S, Pawlotsky JM. Use of virologic assays in the diagnosis and management of hepatitis C virus infection. Clin Liver Dis 2005;9:371-82; v.
17. Fagundes GD, Bonazza V, Ceretta LB, Back AJ, Bettiol J. Detection of the hepatitis C virus in a population of adults. Rev Lat Am Enfermagem 2008;16:396-400
18. Ollier L, Laffont C, Kechkekian A, Doglio A, Giordanengo V. Detection of antibodies to hepatitis B core antigen using the Abbott ARCHITECT anti-HBc assay: analysis of borderline reactive sera. J Virol Methods 2008;154:206-9.
19. Weber B, Van Der Taelem-Brule N, Berger A, Simon F, Geudin M, Ritter J. Evaluation of a new automated assay for hepatitis B surface antigen (HBsAg) detection VIDAS HBsAg Ultra. J Virol Methods 2006;135:109-17.
20. Rabkin CS, Tess BH, Christianson RE, et al. Prospective study of hepatitis C viral infection as a risk factor for subsequent B-cell neoplasia. Blood 2002;99:4240-2.
21. Ohsawa M, Shingu N, Miwa H, et al. Risk of non-Hodgkin's lymphoma in patients with hepatitis C virus infection. Int J Cancer 1999;80:237-9.
22. Duberg AS, Nordstrom M, Torner A, et al. Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology 2005;41:652-9.
23. Crook PD, Jones ME, Hall AJ. Mortality of hepatitis B surface antigen-positive blood donors in England and Wales. Int J Epidemiol 2003;32:118-24.
24. Fwu CW, Chien YC, Nelson KE, etal. Mortality after chronic hepatitis B virus infection: a linkage study involving 2 million parous women from Taiwan. J Infect Dis 2010;201:1016-23.
25. Ulcickas Yood M, Quesenberry CP Jr, Guo D, et al. Incidence of non- Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 2007;46:107-12.
26. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006;368:938-45.
27. Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe-a review. Euro Surveill 2008;13:pii 18880.
28. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev2006;28:112-25.
29. Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol 2007;60:1378-83.
30. Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun 2001;16:269-74.
31. Pasquinelli C, Laure F, Chatenoud L, et al. Hepatitis B virus DNA in mononuclear blood cells. A frequent event in hepatitis B surface antigen-positive and -negative patients with acute and chronic liver disease. J Hepatol 1986;3:95-103.
32. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010; 29:2309-24.
33. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699-712.
34. Talamini R, Montella M, Crovatto M, et al. Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 2004;110:380-5.
35. de Sanjose S, Nieters A, Goedert JJ, et al. Role of hepatitis C virus infection in malignant lymphoma in Spain. Int J Cancer 2004;111: 81-5.
36. Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006;131:1879-86.
37. Schollkopf C, Smedby KE, Hjalgrim H, et al. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 2008;122:1885-90.
38. Zacharakis G, Kotsiou S, Papoutselis M, et al. Changes in the epidemiology of hepatitis B virus infection following the implementation of immunisation programmes in northeastern Greece. Euro Sur- veill 2009;14:pii 19297.
39. World Health Organization, UNAIDS, EU Collaborating Centre on AIDS. HIV/AIDS surveillance in Europe. First half-yearly report 1999. Available from: http://www.eurohiv.org/reports/report-61/pdf/report-eurohiv-61.pdf; 1999.
40. Zuckerman J, van Hattum J, Cafferkey M, et al. Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe? Lancet Infect Dis 2007;7:410-9.